Results 191 to 200 of about 38,631 (238)
Some of the next articles are maybe not open access.
Phosphodiesterase Type 5 (PDE5) Inhibitors
2003Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning +2 more
openaire +2 more sources
How to Evaluate the Efficacy of the Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2012Several methods have been so far proposed to compare the effectiveness of the three available phosphodiesterase type 5 inhibitors (PDE5Is).Two urologists (E.C. and G.B.B.), together with the Controversy's Editor (E.A.J.), with expertise in the area of medical treatment of erectile dysfunction (ED) present the various perspectives on the evaluation of ...
JANNINI, EMMANUELE ANGELO FRANCESCO +3 more
openaire +6 more sources
Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
New England Journal of Medicine, 2009A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the ...
Stephen L, Archer +1 more
openaire +2 more sources
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
Advances in Therapy, 2009Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role.
David, Montani +8 more
openaire +2 more sources
FR226807: a potent and selective phosphodiesterase type 5 inhibitor
European Journal of Pharmacology, 2001We describe the pharmacological characteristics of a novel phosphodiesterase type 5 inhibitor FR226807, N-(3,4-dimethoxybenzyl)-2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide. FR226807 inhibited phosphodiesterase type 5 isolated from human platelets with an IC(50) value of 1.1 nM. FR226807 also inhibited phosphodiesterase type 6 with an IC(50)
N, Hosogai +12 more
openaire +2 more sources
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
Rheumatology International, 2014Raynaud's phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP.
Yasuyuki, Kamata, Seiji, Minota
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviewse, 2011Abuse of sildenafil has been reported since its introduction in 1999 and commonly documented in combination with illicit drugs among men and women of all ages. Increased risks of sexually transmissible diseases including HIV have been associated with sildenafil use in men who have sex with men.
Gregory, Lowe, Raymond, Costabile
openaire +2 more sources
The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction
Expert Opinion on Drug Safety, 2016Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the treatment of erectile dysfunction (ED), being recommended as a first line treatment by both the European and US urological guidelines. PDE5Is are highly effective as compared to placebo, well tolerated and have a very low, though not negligible, rate of severe treatment-related ...
Ventimiglia Eugenio +3 more
openaire +2 more sources
Current Pharmaceutical Design, 2005
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular events in the penile smooth muscle ...
openaire +2 more sources
Nonurologic applications of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Phosphodiesterase type 5 (PDE5) is an enzyme that catalyzes hydrolytic degradation of cyclic guanosine monophosphate, an essential intracellular second messenger that modulates diverse biologic processes in living cells. Three selective inhibitors of PDE5, sildenafil, vardenafil, and tadalafil, have been successfully used by millions of people ...
Rakesh C. Kukreja +2 more
openaire +1 more source